eligibility_summary
Eligible: Histologically confirmed FL grade 1-3a/classic, FFPE <=1 yr or fresh biopsy, no prior systemic therapy (RT/surgery for prior stage I OK), stage II-IV, needs treatment due to bulky disease (>7 cm or >=3 sites >3 cm), B symptoms, splenomegaly below umbilicus, cytopenias (plt<100k, ANC<1.0, Hgb<10), serous effusions, or compressive syndrome. Exclude: transformed lymphoma, FL large cell/grade 3b, significant medical/infection/lab/psychiatric issues, other criteria.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 randomized, open-label trial in newly diagnosed advanced follicular lymphoma tests: 1) Golcadomide (CC-99282/BMS-986369) + rituximab vs 2) Rituximab + chemotherapy (R-CHOP or rituximab+bendamustine). Mechanisms/types: Golcadomide is an oral small-molecule CELMoD (cereblon E3 ligase modulator) that degrades Ikaros (IKZF1) and Aiolos (IKZF3), boosting T- and NK-cell activation, IL-2 production, and direct anti–B-cell effects, it can enhance rituximab-driven ADCC. Rituximab is an anti-CD20 monoclonal antibody causing B-cell depletion via ADCC, complement, and apoptosis. Comparator drugs: cyclophosphamide (alkylating DNA crosslinker), doxorubicin (anthracycline/topoisomerase II inhibitor), vincristine (vinca microtubule inhibitor), prednisone (glucocorticoid inducing lymphocyte apoptosis), bendamustine (alkylator). Targets/pathways: CD20+ malignant B cells, cereblon–IKZF1/3 axis, T/NK cytotoxicity, DNA damage, topoisomerase II, microtubules, glucocorticoid receptor.